
ESTA Stock Forecast & Price Target
ESTA Analyst Ratings
Bulls say
Establishment Labs Hldgs is a medical technology company with a positive outlook due to its strong financials, innovative R&D, and numerous market-expanding catalysts. With above-average revenue growth, attractive gross margin, and a disruptive breast implant technology, the company has potential to capture share from entrenched players in newer markets. Risks include economic recession, competition, unexpected complications, and unsuccessful product launches. The company is valued at $84 based on an EV/sales multiple of 10.0x its 2026E revenue estimate, higher than its peers due to its faster revenue growth.
Bears say
Establishment Labs Hldgs is a medical technology company with a negative outlook due to the delayed timeline for FDA approval for its Motiva label expansion for primary and revision breast reconstruction, which is not expected until 2025. It has potential for future growth with differentiated breast implant technologies and minimally invasive surgical techniques, but potential upside drivers include stronger US Motiva sales and better margins and international growth are unclear due to uncertainties in the FDA review process.
This aggregate rating is based on analysts' research of Establishment Labs Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ESTA Analyst Forecast & Price Prediction
Start investing in ESTA
Order type
Buy in
Order amount
Est. shares
0 shares